Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): Protocol for a randomised controlled double-blind cross-over trial

BMJ Open

Volumn 7, Issue 10, 2017, Pages

  Mordi, Natalie A ^a   Mordi, Ify R ^a   Singh, Jagdeep S ^a   Baig, Fatima ^a   Choy, Anna Maria ^a   McCrimmon, Rory J ^a   Struthers, Allan D ^a   Lang, Chim C ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Diabetes Mellitus; Diuresis; Heart Failure; Natriuresis; Sodium glucose Co transporter 2 (sglt2) Inhibitors

Indexed keywords

ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; EMPAGLIFLOZIN; GLUCOSIDE; LOOP DIURETIC AGENT; SODIUM; SODIUM GLUCOSE COTRANSPORTER 2;

ADOLESCENT; ADULT; AGED; ANTAGONISTS AND INHIBITORS; CHRONIC DISEASE; COMBINATION DRUG THERAPY; COMPLICATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SCOTLAND; URINE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BENZHYDRYL COMPOUNDS; CHRONIC DISEASE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; GLUCOSIDES; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RESEARCH DESIGN; SCOTLAND; SODIUM; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; SODIUM-GLUCOSE TRANSPORTER 2; YOUNG ADULT;

EID: 85031929302     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2017-018097     Document Type: Article

References (27)

1. MacDonald MR, Petrie MC, Hawkins NM, et al. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 2008;29:1224-40.
2. Murcia AM, Hennekens CH, Lamas GA, et al. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch Intern Med 2004;164:2273-9.
3. Krum H, Jelinek M V, Stewart S, et al. Update to National heart foundation of Australia and cardiac society of Australia and New Zhaland guidelines for the prevention, detection and management of chronic heart failure in Australia 2016. 2011;194 http:// eutils. ncbi. nlm. nih. gov/ entrez/ eutils/ elink. fcgi? dbfrom= pubmed& id= 21495941& retmode= ref& cmd= prlinks
4. Forst T, Hanefeld M, Jacob S, et al. Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Diab Vasc Dis Res 2013;10:302-14.
5. Eurich DT, McAlister FA, Blackburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007;335:497.
6. Smooke S, Horwich TB, Fonarow GC. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 2005;149:168-74.
7. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26.
8. Ryden L, Grant PJ, Anker SD, et al. ESC guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2013;34:3035-87.
9. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.
10. Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J 2016;37:1526-34.
11. McMurray J. EMPA-REG - the 'diuretic hypothesis'. J Diabetes Complications 2016;30:3-4.
12. Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation 2016;134:752-72.
13. Škrtić M, Cherney DZ. Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens 2015;24:968p-103.
14. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014;129:587-97.
15. Thomas MC. Renal effects of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab 2014;5:53-61.
16. Sha S, Polidori D, Heise T, et al. Effect of the sodium glucose cotransporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 2014;16:1087-95 http:// ovidsp. ovid. com/ ovidweb. cgi? T= JS& PAGE= reference& D= cctr& NEWS= N& AN= CN-01115818
17. Heise T, Seewaldt-Becker E, Macha S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 2013;15:613-21.
18. Sairaku A, Nakano Y, Kihara Y. Increased urine output by ipragliflozin in a non-diabetic patient with a diuretic-resistant heart failure. Int J Cardiol 2015;180:42-3.
19. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of Kidney disease in type 2 Diabetes. N Engl J Med 2016;375:323-34.
20. Van VDJ, Ruilope LM, Maisel AS, et al. Clinical update biomarkers of renal injury and function : diagnostic, prognostic and therapeutic implications in heart failure. 2016:2577-85.
21. Lang CC, Choy AM, Rahman AR, et al. Renal effects of low dose prazosin in patients with congestive heart failure. Eur Heart J 1993;14:1245-52 http:// onlinelibrary. wiley. com/ o/ cochrane/ clcentral/ articles/ 819/ CN-00096819/ frame. html.
22. Goldsmith SR, Gilbertson DT, Mackedanz SA, et al. Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure. J Card Fail 2011;17:982-9.
23. List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-7.
24. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel Eenergetics explain the beneficial cardiorenal outcomes in the EMPAreg outcome study? A unifying hypothesis. Diabetes Care 2016;39:1115-22.
25. Bebawy JF, Ramaiah VK, Zeeni C, et al. The effect of furosemide on intravascular volume status and electrolytes in patients receiving mannitol: an intraoperative safety analysis. J Neurosurg Anesthesiol 2013;25:51-4.
26. Sirivella S, Gielchinsky I, Parsonnet V. Mannitol, furosemide, and dopamine infusion in postoperative renal failure complicating cardiac surgery. Ann Thorac Surg 2000;69:501-6.
27. Turagam MK, Velagapudi P, Kalra AS, et al. Outcomes of furosemidemannitol infusion in hospitalized patients with heart failure: an observational single-center cohort study of 122 patients. Int J Cardiol 2011;151:232-4.